How does repotrectinib stop cancer cells from growing?
Repotrectinib blocks two protein switches—ROS1 and TRK kinases—that cancer cells use to multiply uncontrollably. By shutting off these switches, the drug starves tumor cells of the growth signals they need, causing them to shrink or stop growing [1][4].
In clinical trials, repotrectinib achieved a 79–85% objective response rate (meaning tumors shrank by at least 30%) in patients with ROS1-positive non-small-cell lung cancer who had never received a kinase inhibitor before [1]. The drug also works against resistance mutations like G2032R and D2033N that make older ROS1 inhibitors stop working [1].
Inside your cells, ROS1 and TRK proteins normally sit quiet. But when a cancer cell has a fusion mutation—where ROS1 or TRK gets stuck to another gene—that protein stays 'on' forever, sending constant grow-grow-grow signals. Repotrectinib acts like a light switch, turning off that stuck-on signal so the cell stops dividing [1][4].
The trade-off is that repotrectinib also affects healthy cells that use ROS1 and TRK, causing side effects like fatigue, diarrhea, and nausea in most patients [6]. Most side effects appear within the first 2–4 weeks and often improve with dose adjustment or supportive care like anti-nausea medication [6][7].
Ask your oncologist: 'Has my tumor been tested for ROS1 or NTRK fusions?' If yes, repotrectinib may be your best option. If no, genetic testing (liquid biopsy or tissue biopsy) takes 1–2 weeks and is usually covered by insurance [1].